Capricor Therapeutics (NASDAQ:CAPR) Raised to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. The brokerage currently has $3.50 price objective on the biotechnology company’s stock.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Other research analysts have also issued research reports about the company. HC Wainwright upped their price target on Capricor Therapeutics from $3.50 to $12.40 and gave the company a buy rating in a research report on Monday, July 15th. ValuEngine raised Capricor Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Finally, Maxim Group reaffirmed a hold rating on shares of Capricor Therapeutics in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $6.63.
Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.21. The business had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.22 million. Capricor Therapeutics had a negative return on equity of 270.78% and a negative net margin of 794.63%. On average, analysts anticipate that Capricor Therapeutics will post -2.87 earnings per share for the current fiscal year.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Story: Death Cross
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.